uptravi tablet
janssen inc - selexipag - tablet - 800mcg - selexipag 800mcg - vasodilating agents
uptravi tablet
janssen inc - selexipag - tablet - 1000mcg - selexipag 1000mcg - vasodilating agents
uptravi tablet
janssen inc - selexipag - tablet - 1200mcg - selexipag 1200mcg - vasodilating agents
uptravi tablet
janssen inc - selexipag - tablet - 1400mcg - selexipag 1400mcg - vasodilating agents
uptravi tablet
janssen inc - selexipag - tablet - 1600mcg - selexipag 1600mcg - vasodilating agents
uptravi 1000 microgram
j-c health care ltd - selexipag - film coated tablets - selexipag 1000 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease
uptravi 1200 microgram
j-c health care ltd - selexipag - film coated tablets - selexipag 1200 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease
uptravi 1400 microgram
j-c health care ltd - selexipag - film coated tablets - selexipag 1400 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease
uptravi 1600 microgram
j-c health care ltd - selexipag - film coated tablets - selexipag 1600 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease
uptravi 200 microgram
j-c health care ltd - selexipag - film coated tablets - selexipag 200 mcg - selexipag - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii-iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease